In The News
September 28, 2022

Follow the Money

Bio-IT World – The agreement grants Sanofi non-exclusive rights to Scribe’s proprietary CRISPR platform of wholly owned enzymes to create ex vivo NK cell therapies.

Read More
September 27, 2022

Sanofi, Scribe Launch Up-to-$1B CRISPR-Based Cancer NK Cell Therapy Collaboration

Genetic Engineering and Biotechnology News – Sanofi and Scribe Therapeutics will partner to develop CRISPR-based cell therapies to fight cancer, the companies said today, through a collaboration that could generate more than $1 billion for the CRISPR drug developer whose co-founders include Nobel laureate Jennifer Doudna, PhD, of UC Berkeley.

Read More
June 29, 2022

Innovators Under 35 2022

MIT Technology Review – As CEO of Scribe Therapeutics, Benjamin Oakes, 33, is working to optimize novel CRISPR enzymes and ways to package the gene-editing systems to solve those problems.

Read More
May 4, 2022

Biogen Pursues Another Neuro Target With Scribe

Inside Precision Medicine – Biogen has exercised an option for an additional disease target in gene therapy with Scribe Therapeutics. This is part of the companies’ ongoing research collaboration to develop and commercialize CRISPR-based therapeutics.

Read More
May 3, 2022

Scribe, Biogen expand ALS CRISPR agreement

Pharma Manufacturing – Scribe, headquartered outside of San Francisco, focuses on creating gene therapies using CRISPR technology and custom engineered enzymes. The company’s custom platforms help it to overcome the technological hurdles that other companies in the field face, said Oakes.

Read More
March 25, 2022

CFOs On the Move

CFO – Biotech firm Scribe Therapeutics appointed David Parrot as chief financial officer. Parrot joins the company from Barclays, where he was a managing director responsible for building its West coast life sciences and biotechnology investment banking business.

Read More
March 11, 2022

Chutes & Ladders

Fierce Biotech – David Parrot is the new CFO of Scribe Therapeutics, a molecular engineering company focused on CRISPR-based meds, after serving as a managing director at investment bank Barclays.

Read More
March 11, 2022

Peer Review

Endpoints News – One of Jennifer Doudna’s CRISPR startups, Alameda, CA-based Scribe Therapeutics, has corralled David Parrot as CFO and George Manning as controller.

Read More
March 11, 2022

BioSpace Movers & Shakers

BioSpace – Life sciences companies continue to bolster their leadership teams as they prepare for the next phase of growth.

Read More
March 10, 2022

Venture Investment in Crispr Gene Editing Spurs Innovation, Hunt for IP

The Wall Street Journal – Scribe Therapeutics Inc., an Alameda, Calif.-based biotech startup also co-founded by Dr. Doudna, is developing custom-engineered enzymes for Crispr-based treatments for neurodegenerative and other diseases. Scribe’s technologies are distinct from earlier approaches, co-founder and CEO Benjamin Oakes said.

Read More
March 10, 2022

Management Tracks

BioCentury – Scribe Therapeutics Inc. hired David Parrot as CFO. Parrot was managing director, head of west coast life science investment banking at Barclays Investment Bank. Scribe is developing custom enzymes and delivery modalities for CRISPR and was co-founded by Jennifer Doudna.

Read More
March 10, 2022

Appointments and advancements

BioWorld – Scribe Therapeutics Inc., of Alameda, Calif., appointed David Parrot chief financial officer and George Manning controller.

Read More
January 5, 2022

Novel Gene Editing Systems Come Into Their Own

Genetic Engineering and Biotechnology News – Scribe scientists hone CasX enzymes so that they acquire characteristics such as enhanced specificity. Oakes describes this as an “engineering first” philosophy, where the desired properties of the system are chosen in advance and intentionally designed, rather than being left to chance or nature.

Read More
October 26, 2021

Biocom Catalyst Awards

Biocom California – Scribe Therapeutics CEO Benjamin Oakes selected as a winner of the 6th annual Catalyst Awards.

Read More
April 12, 2021

5 Novel Therapies Using Synthetic Biology

Nanalyze – The company has raised a whopping $120 million from the likes of Andreessen Horowitz to build out a suite of CRISPR technologies designed to treat genetic diseases.

Read More
April 8, 2021

Engineering CRISPR with Ben Oakes

a16z Bio Clubhouse – a16z general partners Vineeta Agarwala and Vijay Pande talk to guest Ben Oakes, cofounder, President and CEO of Scribe Therapeutics in a conversation on the power of engineering gene editors, the transition from academia to a startup, and how to select the first indication to target with a novel bio platform.

Read More
March 31, 2021

Engineering the Future of Genetic Medicine

Technology Networks – Scribe Therapeutics co-founder and CEO Benjamin Oakes sat down for an interview on the company’s next steps in “fulfilling the promise of CRISPR” and how it will navigate some of the challenges associated with developing CRISPR-based therapeutics, including efficacy, scale-up and high costs.

Read More
December 14, 2020

2020 Was the Turning Point for CRISPR

Medium – Future Human – Scribe Therapeutics of Alameda, California, is using yet another form of CRISPR dubbed X-editing. Co-founded by CRISPR pioneer and Nobel winner Jennifer Doudna, PhD, the company will use the new gene-editing tool to develop treatments for neurological diseases.

Read More
November 3, 2020

Doudna’s Scribe unveils

Nature Biotechnology – Startup Scribe Therapeutics, spun out of Jennifer Doudna’s lab, emerged from stealth on 6 October with a next-generation CRISPR technology, armed with a $20-million series A round and a collaboration with Biogen.

Read More
October 20, 2020

8 Biocom Member Companies Leveraging CRISPR Technology

Biocom – Another of Doudna’s spin-outs, Scribe Therapeutics, just recently announced their plans to build a platform for CRISPR-based genetic medicine to create therapies for diseases like genetically driven ALS. The company’s tools and mission have the potential to dramatically accelerate CRISPR’s applications into the clinical setting.

Read More
October 8, 2020

CRISPR-Based ALS Treatment Being Developed by Scribe and Biogen

Genetic Engineering & Biotechnology News – Best known for her pioneering work in the discovery of CRISPR, Jennifer Doudna, PhD, professor at the University of California, Berkeley, doesn’t stop or, it seems, even slow down. As of yesterday morning, Doudna can add “accept Nobel Prize” to her to-do list as she, along with Emmanuelle Charpentier, PhD, was awarded the 2020 Nobel Prize in Chemistry.

Read More
October 8, 2020

Scribe, Biogen Partner to Develop Gene Therapy for ALS, Other Neurological Diseases

ALS News Today – Founded by the scientists who originally invented CRISPR, Scribe has developed novel, custom-CRISPR tools, using a technology called X-Editing. This advanced gene-editing platform has greater editing activity and higher specificity, meaning that it can edit the target gene with greater precision than other CRISPR tools currently available.

Read More
October 7, 2020

Scribe Therapeutics emerges with $20M, Biogen pact to clear CRISPR hurdles

FierceBiotech – CRISPR evolved in bacteria as a form of “genetic vandalism,” as George Church, Ph.D., puts it, to fend off pathogens. That means it works very well in bacteria but runs into various obstacles when researchers try to put it to work in humans. Jennifer Doudna’s latest CRISPR company plans to surmount those hurdles with an entirely new CRISPR platform that does not rely on molecules found in nature.

Read More
October 6, 2020

Starting with Biogen deal in ALS, Scribe planning a new chapter in CRISPR story

BioWorld – Scribe Therapeutics Inc., another CRISPR-based genome editing firm out of the Jennifer Doudna stable, launched with $20 million in series A funding and a deal with Biogen Inc. in amyotrophic lateral sclerosis (ALS), which brings in another $15 million up front and up to $400 million in development and commercial milestones.

Read More
October 6, 2020

Scribe: engineering CRISPR’s next generation

BioCentury – Scribe is carving out a new space in the gene editing landscape with a next-generation version of the technology from Jennifer Doudna’s lab that substitutes engineered CRISPR enzymes for their natural counterparts.

Read More
October 6, 2020

CRISPR startup Scribe Therapeutics lands big Biogen deal

San Francisco Business Times – Hoping to take the CRISPR genome-editing tool to the next level of drug development, startup Scribe Therapeutics Inc. said Tuesday that it landed a potential $400 million neurodegenerative disease deal with Biogen Inc.

Read More
October 6, 2020

Scribe Therapeutics Sets Out to Write CRISPR Gene Editing’s Next Chapter

Xconomy – The first generation of CRISPR-based therapies showed how the technology can edit DNA, making genetic fixes to unwanted mutations. But those treatments use the CRISPR system as scientists found it in nature, which means it still has limitations when applied to humans, says Benjamin Oakes, CEO of Scribe Therapeutics.

Read More
October 6, 2020

Scribe Therapeutics launches to explore next-generation CRISPR technology

Chemical & Engineering News – Scribe Therapeutics, a biotech firm focused on developing next-generation gene-editing technology, has raised $20 million in its first major round of financing, backed by Andreessen Horowitz. The firm separately unveiled a deal with Biogen to develop CRISPR-based treatments for amyotrophic lateral sclerosis (ALS).

Read More
October 6, 2020

Scribe Therapeutics launches a platform for engineering CRISPR-based therapeutics

TechCrunch – A new company called Scribe Therapeutics founded by two former members of CRISPR pioneer Jennifer Doudna’s UC Berkely genetics lab (alongside Doudna herself) launched on Tuesday, debuting a platform designed specifically to help develop and engineer new therapeutics based on CRISPR for addressing specific diseases, with permanent treatments in patients.

Read More
December 2, 2019

C&EN’s Year in Pharma 2019

Chemical & Engineering News – Jennifer Doudna’s lab at the University of California, Berkeley, published a detailed study on a genetically and structurally distinct CRISPR enzyme called CasX, which makes staggered breaks during its cutting of the DNA double helix.

Read More
More Headlines
Press Releases
Top